Notice NOT-OD-22-171 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-22-209 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The overall scope of this solicitation includes validation of therapeutic targets and preclinical characterization of lead compounds. The UG3 phase of this FOA supports target validation and characterization of initial lead compound(s); UH3 phase activities include candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. At the conclusion of the overall UG3/UH3 funding period, projects are expected to deliver at least one well-characterized therapeutic candidate.

Notice NOT-OD-22-170 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-174 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-169 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-173 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-172 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-23-046 from the NIH Guide for Grants and Contracts. This FOA solicits applications for multi-disciplinary RM1 Research Centers (RM1s) that involve partnerships between researchers and payors, health plans, single state agencies/opioid treatment authorities, professional organizations, or other entities. Relevant partners have a deployed or in-development quality measurement and management strategy or system that does or could inform provider or clinician selection and treatment improvement and that rigorous research could substantially advance. Activities should also support the acceptability of the quality measurement and management system to patients, clinicians, and providers; the feasibility, scalability, and sustainability of the system; and equity in quality provider selection and treatment delivery.

Notice NOT-HL-22-036 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-156 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-23-029 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Research and Entrepreneurial Development Immersion (REDI) Small Business Innovation Research (SBIR) Grant applications. The goal of this FOA is to foster the career development of early-career scientists with an interest in entrepreneurship by simultaneously supporting their entrepreneurial development and facilitating their transition to industry. This FOA utilizes the R43/R44 Industry Development Award to provide small business concerns (SBCs) the opportunity to support the hiring and salary of postdoctoral fellows and early-stage researchers as Principal Investigators/Program Directors (PIs/PDs) to increase their scientific research staff and support product development. Additionally, a major component of this FOA is a strong focus on entrepreneurial training, mentoring, and career development of the PD/PI. Postdoctoral fellows and early-career researchers with strong research skills and experience in technology discovery, and that have an interest in growing their entrepreneurial skillset and working in the industry, are optimal PD/PIs for this award.

Funding Opportunity RFA-AG-23-030 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Research and Entrepreneurial Development Immersion (REDI) Small Business Technology Transfer Research (STTR) Grant applications. The goal of this FOA is to foster the career development of early-career scientists with an interest in entrepreneurship by simultaneously supporting their entrepreneurial development and facilitating their transition to industry. This FOA utilizes the R41/R42 Industry Development Award to provide small business concerns (SBCs) the opportunity to support the hiring and salary of postdoctoral fellows and early-stage researchers as Principal Investigators/Program Directors (PIs/PDs) to increase their scientific research staff and support product development. Additionally, a major component of this FOA is a strong focus on entrepreneurial training, mentoring, and career development of the PD/PI. Postdoctoral fellows and early-career researchers with strong research skills and experience in technology discovery, and that have an interest in growing their entrepreneurial skillset and working in the industry, are optimal PD/PIs for this award. Given that the purpose of this FOA is to facilitate the PDs/PIs' transition to the SBC, most of their employment must be at the SBC.

Notice NOT-MH-22-265 from the NIH Guide for Grants and Contracts

Notice NOT-RM-22-018 from the NIH Guide for Grants and Contracts

Notice NOT-HG-22-023 from the NIH Guide for Grants and Contracts

Notice NOT-AR-22-023 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-105 from the NIH Guide for Grants and Contracts

Notice NOT-HL-22-035 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-23-017 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for the Claude D. Pepper Older Americans Independence Centers (OAIC) award. The goal of the OAIC program is to establish centers of excellence in geriatrics research and research education to increase scientific knowledge leading to better ways to maintain or restore independence in older persons. OAIC awards are designed to develop or strengthen programs that focus on and sustain progress in a key area in aging research related to the mission of the OAIC program.

Funding Opportunity PAR-22-211 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for basic and translational research on the impact of the microbiome on Alzheimers Disease and Alzheimers Disease Related Dementias (AD/ADRD). While there is growing evidence that the microbiome is an important factor that contributes to overall health and a variety of diseases and disorders, the role of the alimentary canaland other sources of endogenous microbiota in specific AD/ADRDs has not been adequately addressed. This FOA will support mechanistic research focused on a more rigorous in-depth examination of the potential interactions between the microbiome and genetic and non-genetic molecular targets that influence AD/ADRD. It is expected that these studies will address the clinical relevance of the microbiome on disease initiation, progression, or modification, and will lead ultimately to better therapeutic interventions.